Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONALEESA-3 ribociclib plus fulvestrant in HR-positive/HER2-negative advanced breast cancer
NL-OMON55639Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Ribociclib + fulvestrant with Placebo + fulvestrant (2 arms). Primary endpoint: progression-free survival. Started Jul 2015; status: active, not recruiting.
02
Drugs
ribociclibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON55639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55639.